Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Erasca (Nasdaq: ERAS) updated preliminary Phase 1 AURORAS-1 data for ERAS-0015. In 2L+ KRAS G12X pancreatic cancer at 32 mg QD, it reported 57% uORR (N=7) and generally well-tolerated safety with no DLTs. In a panitumumab combo, no DLTs occurred in a 16 mg cohort. Company plans potential registration-enabling trials in lung and pancreatic cancers in 2027.
How this was made
The 30-second read
Why it matters
The update adds more patients and longer follow-up, reiterates generally well-tolerated monotherapy with no DLTs in the first panitumumab combination escalation cohort, and lays out a timeline for potentially registration-enabling trials in NSCLC and pancreatic cancer.
Market read
Traders get a fresh efficacy/safety snapshot plus a concrete Phase 3 development timetable, which can re-rate probability of success for ERAS-0015.
What to watch
The press release is preliminary with specific data cutoffs (May 25, 2026 and July 6, 2026). Combination outcomes with panitumumab and the feasibility of registration-enabling endpoints are not yet demonstrated.
Background
Erasca is developing ERAS-0015, an oral pan-RAS molecular glue, in its AURORAS-1 Phase 1 trial across RAS-mutant solid tumors.
Ticker impact
Erasca reported updated Phase 1 AURORAS-1 data for ERAS-0015, including 57% uORR at 32 mg QD and plans for potentially registration-enabling Phase 3 trials.
Near-term upside bias as traders price in improved response durability and clearer regulatory path; volatility likely around future H1 2027 data readouts.
The article discloses new preliminary patient data (additional patients and longer follow-up) and specific trial initiation timing (H1 2027, 2027, H2 2027 to H1 2028), which can shift probability-weighted outcomes for a clinical-stage biotech. However, it remains Phase 1 and preliminary, limiting conviction.
Market effects
Supports sentiment for KRAS/MAPK pathway molecular glue and pan-RAS strategies, potentially improving risk appetite for similar early-stage oncology names.
Limited direct regional impact; primarily US biotech sentiment.
Moderate, as KRAS-mutant solid tumor development is globally relevant but the update is early-stage and company-specific.
Counterpoint
High uORR in a small Phase 1 cohort may not translate into Phase 3 efficacy; traders may fade the move if durability, confirmatory endpoints, or biomarker stratification disappoint.
Key entities
- companyErasca, Inc.
Nasdaq-listed clinical-stage precision oncology company developing ERAS-0015.
- drug_programERAS-0015
Investigational oral pan-RAS molecular glue evaluated in AURORAS-1.
- clinical_trialAURORAS-1
Ongoing Phase 1 trial in RAS-mutant solid tumors.
- drugpanitumumab
Commercially approved antibody used in a combination cohort with ERAS-0015 in metastatic colorectal cancer.
